David Pernock, Chairman of the Board and CEO, joined Fibrocell Science with extensive leadership experience in healthcare sales and commercialization, building business units, partnerships, and brands, most recently as senior vice president, Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care and HIV at GlaxoSmithKline. Over a long career at GlaxoSmithKline, Mr. Pernock was promoted numerous times to levels of increasing responsibility including vice president of Marketing, Pharmaceuticals; vice president of Sales and Marketing, Oncology; vice president of Managed Care; and, vice president of Sales. Mr. Pernock holds a BS in Business Administration from Arizona State University. He serves on many philanthropic organizations.

Declan Daly was named Chief Operating Officer and Chief Financial Officer of Fibrocell Science, Inc. in September 2009. Prior to the reorganization of Isolagen, Inc. as Fibrocell, he had served as Chief Executive Officer of Isolagen. He originally joined Isolagen as Chief Financial Officer (CFO) and Executive Vice President - Europe in June 2006, and was promoted to Chief Operating Officer and CFO in June 2007. Prior to joining Isolagen, Mr. Daly spent more than seven years with Inamed Corporation and most recently served as CFO. Prior to becoming CFO, Mr. Daly served as Inamed's Senior Vice President, Corporate Controller and Principal Accounting Officer, and previously as Vice President of Finance & Administration of Inamed International Corp. based in Europe. Mr. Daly holds a BA in Management Science and Industrial Systems Studies from Trinity College in Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.

Paul A. Hopper is currently managing director at the Los Angeles based investment bank Cappello Group. With more than 20 years experience in international public company markets - primarily in the medical, healthcare and biotechnology sectors, Mr. Hopper has focused much of his business efforts on start-up and rapid-growth companies, and has served as either chairman, CEO or non-executive director of thirteen public companies in Australia, the United States and Asia. In addition to his role as Chairman of the oncolytic virus company Viralytics Ltd,, Mr. Hopper is also a director of pSivida Corp, a drug delivery company, and Somnomed Limited, which globally manufactures and markets a dental device for sleep disorders. Educated at The King's School, he holds a degree in political science from The University of New South Wales (B.A.), the Diploma from the Securities Institute of Australia (A.S.I.A.) and has attended the Harvard Business School advanced management program on three occasions.

George J. Korkos currently serves as President of both Plastic Surgery Associates and Rejuva Skin Care & Laser Center (leaders in use of Botox® and fillers), each of which is located in Waukesha, Wisconsin. He also presently serves as Associate Clinical Professor at the Medical College of Wisconsin in Milwaukee. Dr. Korkos was board certified in plastic surgery in 1967 and recertified in 1978. He is or has been a member of numerous prestigious medical societies, is an experienced academic lecturer and author and has presented on a variety of plastic and reconstructive surgery topics at meetings of regional and national medical associations. He has previously served as scientific advisory board member to Cellgen Company, Sleep Holding Company and Skin Visible Company. He also is Co-founder and former Contact Director and Investor of the Milwaukee Bucks Expansion Basketball Team, which won the National Basketball Association championship in 1971 NBA Champions – three years after the team’s creation. Dr. Korkos pursued undergraduate studies at Marquette University, received his D.D.S. from Marquette University School of Dentistry, his M.D. and general surgery degrees from Medical College of Wisconsin, and his degree in plastic and reconstructive surgery from St. Louis University Medical School. He completed his residencies and held fellowships at Medical College of Wisconsin and St. Louis University Group of Hospitals.

Robert S. Langer is an engineer and the David Koch Institute Professor at the Massachusetts Institute of Technology. He was formerly the Germeshausen Professor of Chemical and Biomedical Engineering and remains active in the department of chemical engineering and the department of biological engineering at MIT. He is also a faculty member of the Harvard-MIT Division of Health Sciences and Technology. Dr. Langer is a widely recognized and cited researcher in biotechnology, especially in the fields of drug delivery systems and tissue engineering. Dr. Langer's research laboratory at MIT is the largest biomedical engineering lab in the world. Dr. Langer is widely regarded for his contributions to medicine and the emerging fields of biotechnology. He is considered a pioneer of many new technologies, including transdermal delivery systems, which allow the administration of drugs or extraction of analytes from the body through the skin without needles or other invasive methods. He is a prolific inventor and holds more than 750 granted or pending patents. He has also authored more than 1,000 scientific papers and has participated in the founding of multiple technology companies. He has received numerous awards, including the National Medal of Science, the Charles Stark Draper Prize, the Lemelson-MIT Prize, the Albany Medical Center Prize in Medicine and Biomedical Research and the Millennium Technology Prize in 2008. Dr. Langer received his bachelor's degree from Cornell University in chemical engineering. He earned his Sc.D. in chemical engineering from MIT in 1974.

Marc B. Mazur is the Chairman of Elsworthy Capital Management Ltd., a London-based European equity hedge fund with assets in excess of $100 mm. Most recently, he was the CEO of Brevan Howard U.S. Asset Management, the U.S. arm of London-based Brevan Howard, the largest hedge fund in Europe. Prior to joining Brevan Howard, Mr. Mazur had been a senior advisor to both Tsinghua Venture Capital Company (a subsidiary of Tsinghua Holdings, the investment arm of Tsinghua University in Beijing) and Think Equity Partners LLC, a San Francisco investment bank focusing on emerging growth companies in biotechnology, software and greentech. A consultant and private investor, Mr. Mazur has more than 25 years of experience in risk management, business development and senior level sales and marketing in the financial services and health care fields. He began his career in 1984 at Salomon Brothers in London as a Eurobond trader. In 1987 he joined Goldman Sachs as a Vice President in the fixed income division. He was employed by Goldman from 1987 through 1996 on a full-time basis and subsequently as a consultant from 1997 through 1999. In 1997 Mr. Mazur became an independent consultant, managing business development opportunities in the financial services sector for Goldman Sachs and leveraging his expertise in risk and disease management for public and private companies in the healthcare field. Continuing in healthcare, in 1998 Mr. Mazur was named Vice President for strategic business development at CareInsite (subsequently acquired by WebMD). In 2001 Mr. Mazur founded Ambassador Capital Group, a privately held investment and advisory entity providing capital, business development and strategic planning advice to companies in the healthcare, financial services and real estate fields. He has also been an active angel and venture investor in numerous biotechnology and healthcare device start-ups. Mr. Mazur is an active member of numerous charitable and educational organizations and has served as a board member and advisory board member of numerous public and private companies. He received his B.A. in political science from Columbia University in 1981 and a J.D. from Villanova University in 1984.